



Basimglurant

Catalog No: tcsc3388

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 802906-73-6
Formula: C ₁₈ H ₁₃ CIFN ₃
Pathway: GPCR/G Protein
Target: mGluR
Purity / Grade: >98%
Solubility: DMSO : ≥ 33.33 mg/mL (102.31 mM); H2O :
Alternative Names: RG7090;CTEP Derivative
Observed Molecular Weight: 325.77





Product Description

Basimglurant (RG7090) is a potent, selective and orally available **mGlu5** negative allosteric modulator with a K_d of 1.1 nM.

IC50 & Target: Kd: 1.1 nM (mGlu5)^[1]

In Vitro: $[^3H]$ -basimglurant saturation analysis on recombinant human mGlu5 reveals monophasic saturation isotherms with K_d of 1.1 nM. In competition binding experiments on human recombinant mGlu5, Basimglurant (RG7090) fully displaces $[^3H]$ -MPEP with a K of 35.6 nM and $[^3H]$ -ABP688 with a K_i of 1.4 nM. In HEK293 cells stably expressing human mGlu5, Basimglurant (RG7090) inhibits quisqualate induced Ca^{2+} mobilization with an IC_{50} of 7.0 nM and $[^3H]$ -inositolphosphate accumulation with an IC_{50} of 5.9 nM. Basimglurant (RG7090) shows similar potencies in radioligand binding and functional assay on human and rodent mGlu5 receptor orthologues $[^1]$.

In Vivo: Basimglurant (RG7090) is a potent, selective, and safe mGlu5 inhibitor with good oral bioavailability and long half-life supportive of once-daily administration, good brain penetration, and high *in vivo* potency. It has antidepressant properties which are corroborated by its functional magnetic imaging (fMRI) profile, as well as anxiolytic-like and antinociceptive features^[1]. It is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. In the Vogel conflict drinking test, Basimglurant dose dependently increases the drinking time. The total plasma exposure of efficacious doses of Basimglurant (RG7090) ranges from 5 ng/mL (0.03 mg/kg) to 37 ng/mL (0.3 mg/kg)^[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!